

# Cathepsin S Therapeutic and Overview Pipeline Review H2

*Cathepsin S Treatment Pipeline Review H2 2016*

PUNE, INDIA, November 14, 2016

/EINPresswire.com/ -- The report provides comprehensive information on the [Cathepsin S](#) (CTSS or EC 3.4.22.27), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive

pharmacological action of the

therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics development and features dormant and discontinued projects.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/740520-cathepsin-s-ctss-or-ec-3-4-22-27-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

## Scope

- The report provides a snapshot of the global therapeutic landscape for Cathepsin S (CTSS or EC 3.4.22.27)



WISE GUY  
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

- The report reviews Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics

#### Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cathepsin S (CTSS or EC 3.4.22.27)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cathepsin S (CTSS or EC 3.4.22.27) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

#### Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Cathepsin S (CTSS or EC 3.4.22.27) Overview 6

Therapeutics Development 7

Cathepsin S (CTSS or EC 3.4.22.27) - Products under Development by Stage of Development 7

Cathepsin S (CTSS or EC 3.4.22.27) - Products under Development by Therapy Area 8

Cathepsin S (CTSS or EC 3.4.22.27) - Products under Development by Indication 9

Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Products Glance	10
Late Stage Products	10
Early Stage Products	11
Cathepsin S (CTSS or EC 3.4.22.27) - Products under Development by Companies	12
Cathepsin S (CTSS or EC 3.4.22.27) - Therapeutics Assessment	14
Assessment by Monotherapy/Combination Products	14
Assessment by Mechanism of Action	15
Assessment by Route of Administration	16
Assessment by Molecule Type	17
Cathepsin S (CTSS or EC 3.4.22.27) - Companies Involved in Therapeutics Development	19
Amura Holdings Limited	19
F. Hoffmann-La Roche Ltd.	20
Fusion Antibodies Limited	21
Sanofi	22
Virobay Inc.	23
Cathepsin S (CTSS or EC 3.4.22.27) - Drug Profiles	24
AM-3840 - Drug Profile	24
Product Description	24
Mechanism Of Action	24
R&D Progress	24
AM-3876 - Drug Profile	25
Product Description	25
Mechanism Of Action	25
R&D Progress	25
Fsn-0503h - Drug Profile	26
Product Description	26
Mechanism Of Action	26
R&D Progress	26
RG-7625 - Drug Profile	27
Product Description	27
Mechanism Of Action	27
R&D Progress	27
RO-5461111 - Drug Profile	28
Product Description	28
Mechanism Of Action	28
R&D Progress	28
SAR-114137 - Drug Profile	29

Access Report @ <https://www.wiseguyreports.com/reports/740520-cathepsin-s-ctss-or-ec-3-4-22-27-pipeline-review-h2-2016>

Get in touch:

LinkedIn: [www.linkedin.com/company/4828928](http://www.linkedin.com/company/4828928)

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/353793834>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.